NOVN Novan Inc.

2.13
+0.01  (+0%)
Previous Close 2.12
Open 2.18
Price To Book -2.07
Market Cap 56,903,708
Shares 26,715,356
Volume 23,138
Short Ratio
Av. Daily Volume 41,469
Stock charts supplied by TradingView

NewsSee all news

  1. Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

    MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric

  2. Novan Awarded Approximately $1.1 Million Grant by Department of Defense

    Funds to progress women's health product candidate, WH504Additive to recently announced NIH grant for WH602Women's health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept.

  3. Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock

  4. Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

    MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the

  5. Novan Hires Michelle Patterson as Vice President of Project Management

    Underscores Company's preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results are expected no later

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 data due no later than early 1Q 2020.
SB206
Molluscum contagiosum skin infection
Phase 2 trial to be initiated 4Q 2019.
SB414
Atopic Dermatitis

Latest News

  1. Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

    MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric

  2. Novan Awarded Approximately $1.1 Million Grant by Department of Defense

    Funds to progress women's health product candidate, WH504Additive to recently announced NIH grant for WH602Women's health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept.

  3. Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock

  4. Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

    MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the

  5. Novan Hires Michelle Patterson as Vice President of Project Management

    Underscores Company's preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results are expected no later

  6. Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

    MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment